01:21 , Dec 8, 2018 |  BioCentury  |  Strategy

Novo gets serious about AI-guided drug design

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...
00:41 , Mar 25, 2017 |  BioCentury  |  Strategy

Mountain climbing

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...
08:00 , Nov 2, 2015 |  BioCentury  |  Finance

Same name, different dollars

After nearly 25 years, Frazier Healthcare is separating its life sciences venture investments from its growth buyouts. Both groups will still operate under the Frazier name, but the new $262 million Frazier Life Sciences VIII...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

Calibrium, Novo Nordisk deal

Novo will acquire biopharma Calibrium for an undisclosed sum. The company develops therapeutics to treat diabetes and other metabolic diseases. Novo said the acquisition, expected to close this quarter, will expand its portfolio and research...